Abstract Antibody–drug conjugates (ADCs)—a groundbreaking class of agents for targeted
oncological therapies—consist of monoclonal antibodies with strong antigenic specificity …

Breast cancer (BC) is the most commonly diagnosed malignancy and represents a major
cause of death in women worldwide. 1 The metastatic pattern of spread is a major …

Patients with HER2-positive breast cancer account for approximately 15% to 20% of all
breast cancers and represent one of the most aggressive breast cancer subtypes. Survival …

The results of the Phase III DESTINY-Breast04 trial of trastuzumab deruxtecan (T-DXd) are
leading to a shift in both the classification and treatment of human epidermal growth factor …

Breast cancer (BC) poses a severe threat to the health of women worldwide. Currently,
different therapeutic regimens are used for BC according to the pathological classification of …

人表皮生长因子受体2 (human epidermal growth factor receptor 2, HER2)
阳性乳腺癌患者易发生脑转移. 血脑屏障/血肿瘤屏障导致药物递送效率低是脑转移系统治疗 …

In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2
positive breast cancer were published. To bring this new evidence into a clinical …